DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1

告示番号

疾患名（ページ内リンク）

臨床試験数

多発性硬化症／視神経脊髄炎

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00109161 (ClinicalTrials.gov)	April 2005	22/4/2005	Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis	A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis	Multiple Sclerosis	Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)	PDL BioPharma, Inc.	NULL	Completed	18 Years	55 Years	Both	270	Phase 2	United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00109161
(ClinicalTrials.gov)

April 2005

22/4/2005

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)

PDL BioPharma, Inc.

NULL

Completed

18 Years

55 Years

Both

270

Phase 2

United States;Canada